文献速递头颈部肿瘤放疗

口咽癌根治性放疗后12周FDG-PET/CT疗效评估:p16状态的影响

FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status.
PubMed 文献 · Radiother Oncol · 2020-04-01

本研究回顾性分析口咽鳞癌根治性放疗后FDG-PET/CT的预测价值,比较p16阳性与阴性患者。结果显示FDG-PET/CT的阴性预测值极佳,但p16阳性者的阳性预测值显著低于p16阴性者,且12周内检查的预测价值可能更差。完全代谢缓解与显著改善的总生存相关。

要点

  • FDG-PET/CT的阴性预测值不受p16状态影响,均接近100%。
  • p16阳性者的局部和区域阳性预测值显著低于p16阴性者。
  • 12周内行FDG-PET/CT可能降低p16阳性者的预测价值。

核心结论

  • 根治性放疗后FDG-PET/CT的代谢反应阴性预测值极佳,不受p16状态影响。
  • p16阳性者的阳性预测值显著低于p16阴性者,区域特异性亦显著降低。
  • 完全代谢缓解与显著改善的5年总生存相关。

研究设计与样本

  • 回顾性分析2012至2016年在本机构接受根治性放疗的口咽鳞癌患者。
  • 共纳入556例p16阳性及92例p16阴性患者,中位随访32个月。
  • 以病理、后续FDG-PET/CT或临床随访为参考标准。

主要发现

  • FDG-PET/CT中位检查时间为放疗结束后96天,68%达完全代谢缓解。
  • 局部阳性预测值p16阳性26% vs p16阴性54%(p=0.01),区域阳性预测值31% vs 58%(p=0.01)。
  • 局部阴性预测值均为100%,区域阴性预测值p16阳性100% vs p16阴性99%(p=0.33)。
  • p16阳性者中,≤12周检查的区域特异性76.2% vs >12周91.1%(p=0.0003)。
  • 完全代谢缓解者5年总生存87% vs 无完全代谢缓解者51%(p≤0.001)。

关键数值与推荐

  • 完全代谢缓解定义为轻度非局灶或无摄取。
  • p16阳性者≤12周检查的局部阳性预测值0 vs >12周30%(p=0.06)。
  • p16阳性者≤12周检查的区域阳性预测值12% vs >12周35%(p=0.06)。

临床怎么用

  • FDG-PET/CT阴性结果可可靠排除残留病灶,支持避免不必要的干预。
  • 对p16阳性患者,阳性FDG-PET/CT结果需谨慎解读,建议结合临床或病理确认。
  • p16阳性患者若在放疗后12周内检查,阳性预测价值可能更低,需考虑检查时机。

局限性

  • 回顾性单中心研究,可能存在选择偏倚。
  • FDG-PET/CT检查时间范围较宽(45-744天),异质性较大。
  • 参考标准不统一,部分依赖临床随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the predictive value of FDG-PET/CT for detection of residual disease after radical radiotherapy for patients with squamous cell carcinoma (SCC) of the oropharynx, comparing p16 positive (+) versus p16 negative (-) disease. METHODS AND MATERIALS: A retrospective analysis of patients with SCC of the oropharynx at our institution treated with radical radiotherapy between 2012 and 2016 was performed. The primary and lymph node metabolic responses were evaluated independently on the post-treatment FDG-PET/CT. The reference standard was pathology when available, subsequent post-treatment FDG-PET/CT results or clinical follow-up. RESULTS: Median follow-up time was 32 (30-34) months. 556 patients had p16+ disease and 92 had p16- disease. The median time of post-treatment FDG-PET/CT was 96 (45-744) days after radiotherapy completion: 68% had complete metabolic response (CMR) defined as mild non-focal or no uptake, 10% residual primary disease, 11% residual regional lymph node disease, 5% residual primary and regional disease, and 6% distant metastatic disease. The local positive predictive value (PPV) was 26% for p16+ versus 54% for p16- (p = 0.01) and the regional PPV was 31% for p16+ versus 58% for p16- (p = 0.01). The local negative predictive value (NPV) was 100% regardless of p16 status and the regional NPV was 100% for p16+ versus 99% for p16- (p = 0.33). For p16+ cases, regional specificity was 76.2% versus 91.1% (p = 0.0003), local PPV was 0 versus 30% (p = 0.06) and the regional PPV was 12% versus 35% (p = 0.06) for FDG-PET/CT scans performed at ≤12 weeks versus >12 weeks. Five-year overall survival for those with CMR was 87% versus 51% without CMR (p ≤ 0.001). CONCLUSIONS: Metabolic response on post-treatment FDG-PET/CT has excellent NPV regardless of p16 status. The PPV is significantly lower in those with p16+ versus p16- disease, with a significantly reduced regional specificity and a trend towards inferior predictive value if performed ≤12 weeks. CMR predicts for a significantly improved overall survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Urban R, Godoy T, Olson R, et al. FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status. Radiother Oncol. 2020. PMID: 32294581. doi:10.1016/j.radonc.2020.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。